283 related articles for article (PubMed ID: 35995984)
1. Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer.
Zhang L; Wang Y; Meng W; Zhao W; Tong Z
Sci Rep; 2022 Aug; 12(1):14312. PubMed ID: 35995984
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
3. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
4. Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study.
Feng Y; Qin Z; Yang Z
J Clin Pharm Ther; 2021 Feb; 46(1):93-98. PubMed ID: 32975332
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of novel HER2-targeted therapies.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
[TBL] [Abstract][Full Text] [Related]
6. Cardiac function in women receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer.
Zekri J; Rasool H; Rizvi SAJ; Eldeeb H; Al-Gahmi A; Farag K; Rasmy A
Womens Health (Lond); 2023; 19():17455057231166837. PubMed ID: 37148305
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
[TBL] [Abstract][Full Text] [Related]
8. The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
Bouwer NI; Steenbruggen TG; Rier HN; Kitzen JJEM; Smorenburg CH; van Bekkum ML; de Jong PC; Drooger JC; Holterhues C; Kofflard MJM; Boersma E; Sonke GS; Levin MD; Jager A
Int J Cancer; 2022 Aug; 151(4):616-622. PubMed ID: 35403708
[TBL] [Abstract][Full Text] [Related]
9. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy.
Cheng S; Wang J; Wang Y; Qi L; Li F; Liu J; Chen J; Fan Y; Xie L
Eur Radiol Exp; 2023 May; 7(1):22. PubMed ID: 37183212
[TBL] [Abstract][Full Text] [Related]
11. Correlation of High-Sensitivity Cardiac Troponin I Values and Cardiac Radiation Doses in Patients with Left-Sided Breast Cancer Undergoing Hypofractionated Adjuvant Radiotherapy with Concurrent Anti-HER2 Therapy.
Antunac K; Mayer L; Banovic M; Beketic-Oreskovic L
Curr Oncol; 2023 Oct; 30(10):9049-9062. PubMed ID: 37887554
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.
Khoury K; Lynce F; Barac A; Geng X; Dang C; Yu AF; Smith KL; Gallagher C; Pohlmann PR; Nunes R; Herbolsheimer P; Warren R; Srichai MB; Hofmeyer M; Asch F; Tan M; Isaacs C; Swain SM
Breast Cancer Res Treat; 2021 Feb; 185(3):863-868. PubMed ID: 33400034
[TBL] [Abstract][Full Text] [Related]
13. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
14. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
Hussain Y; Drill E; Dang CT; Liu JE; Steingart RM; Yu AF
Breast Cancer Res Treat; 2019 May; 175(1):239-246. PubMed ID: 30721443
[TBL] [Abstract][Full Text] [Related]
15. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
16. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
[TBL] [Abstract][Full Text] [Related]
17. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.
de Azambuja E; Agostinetto E; Procter M; Eiger D; Pondé N; Guillaume S; Parlier D; Lambertini M; Desmet A; Caballero C; Aguila C; Jerusalem G; Walshe JM; Frank E; Bines J; Loibl S; Piccart-Gebhart M; Ewer MS; Dent S; Plummer C; Suter T;
ESMO Open; 2023 Feb; 8(1):100772. PubMed ID: 36681013
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Bouwer NI; Steenbruggen TG; van Rosmalen J; Rier HN; Kitzen JJEM; van Bekkum ML; Tije AJT; de Jong PC; Drooger JC; Holterhues C; Smorenburg CH; Kofflard MJM; Boersma E; Sonke GS; Levin MD; Jager A
Breast Cancer Res Treat; 2021 Apr; 186(3):851-862. PubMed ID: 33394273
[TBL] [Abstract][Full Text] [Related]
19. Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy.
Huang P; Huang JH; Zheng YB; Cao WM; Shao XY; Chen JQ; Huang Y; Li GL; Sharma K; Zhou HH; Wang XJ; Jin HC; Chen ZH
Front Pharmacol; 2022; 13():883600. PubMed ID: 35991878
[No Abstract] [Full Text] [Related]
20. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
